SCHEMBL3485770

SCHEMBL3485770

CCOC(=O)C(C)(C)c1ccc2[nH]c(-c3cc(F)cc(F)c3)cc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 1/20 0.42
CNR2 P34972 5/20 0.39
F10 P00742 2/20 0.39
CYP1A1 P04798 1/20 0.39
ASIC3 Q9UHC3 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
MMP2 P08253 1/20 0.36
MMP13 P45452 1/20 0.36
MMP14 P50281 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8165963 0.93 PTGDR2 (0.41) KCNQ2CNR2F10CYP1A1ASIC3
SCHEMBL3485495 0.91 KCNQ2 (0.47) KCNQ2CNR2F10CYP1A1KDM4E
SCHEMBL3485556 0.88 CNR2 (0.52) KCNQ2CNR2F10ASIC3KDM4E
SCHEMBL3485725 0.88 PTGDR2 (0.43) KCNQ2CNR2F10KDM4EALDH1A1
SCHEMBL3485857 0.86 PPARG (0.50) KCNQ2CNR2F10KDM4EALDH1A1
SCHEMBL3485248 0.85 CNR2 (0.44) KCNQ2CNR2F10ASIC3KDM4E
SCHEMBL3484803 0.84 FFAR1 (0.43) KCNQ2CNR2F10CYP1A1KDM4E
SCHEMBL3485512 0.83 KCNQ2 (0.62) KCNQ2CNR2F10KDM4EALDH1A1
SCHEMBL3484832 0.83 KCNQ2 (0.48) KCNQ2F10KDM4EALDH1A1HPGD
SCHEMBL3485915 0.83 CYP26A1 (0.46) KCNQ2CNR2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087446-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK SHARP & DOHME CORP. 2010-04-08 US disclosed
US-20100087446-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK SHARP & DOHME CORP. 2010-04-08 US disclosed
US-20100087446-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK SHARP & DOHME CORP. 2010-04-08 US disclosed
WO-2008133867-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087446-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, CACNA1S, TRPV2 KCNQ2 103/4885CNR2 66/4885F10 3950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.